Biohaven rises on positive early-stage antibody drug trial results
16/12/2024 13:33
** Shares of drug developer Biohaven BHVN.N rise 2.7% to
$39.5 premarket
** BHVN says its experimental drug, BHV-1300, reduced
targeted Immunoglobulin G, a type of antibody, by more than 60%
in an early-stage clinical trial
** BHVN partnered with Ypsomed to develop an autoinjector
for BHV-1300, co says
** All 15 brokerages rate the stock "buy" or higher; their
median PT is $63 - LSEG
** As of last close, stock has fallen ~10% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Recent news on Biohaven
See all newsActing US FDA chief meets with rare disease groups to mend fences (updated)
Acting US FDA chief meets with rare disease groups to mend fences
Brief: Biohaven Reports New Clinical Data In Epilepsy With Opakalim, A Selective Kv7.2/7.3 Activator, Highlighting Seizure Control And Markedly Differentiated Tolerability Profile
Brief: Biohaven Files For Offering Of Up To $350 Million Common Shares - SEC Filing
Brief: Biohaven Ltd Files For Mixed Shelf Offering Size Not Disclosed - SEC Filing